BioInsights - Leveraging oncology gene expression signatures to accelerate research

Leveraging oncology gene expression signatures to accelerate research

Immuno-Oncology Insights 2022; 3(7), 357

DOI: 10.18609/ioi.2022.037

Published: 5 July 2022
Sarah Church

Watch the video or read the poster to learn about:

  • Expression panels containing signatures (TIS, PAM50, LST, and 48 biological signatures), complemented by data analysis services
  • How expression signatures can vastly improve the statistical power and interpretation of data
  • How analysis reports can help expedite research – understand the statistics available, explore the publication-ready figures provided, and understand the consultation provided by Nanostring scientists
  • The framework and processes that went into developing the signatures

Sarah Church focuses on developing and applying NanoString platforms to address key research areas in immunology and oncology. As part of that mission, Sarah works with academics, biopharmas, and clinicians to identify unmet needs in translational research and create novel products for transcriptional and proteomic profiling. Sarah oversees strategic collaborations to help investigators utilize NanoString tools in their research with the goal of developing new biomarkers that can be deployed as clinical diagnostics. Sarah also leads our data analysis service team to support customers to get the most out of their NanoString data. Prior to joining NanoString, Sarah worked on developing immune-based predictive and prognostic biomarkers for solid tumors at INSERM in Paris, France. Sarah has a PhD in molecular microbiology and immunology from Oregon Heath and Sciences University and BA in biology from Scripps College.